share_log

礼来美股盘前涨超2%,公司在首次对比试验中击败诺和诺德

Eli Lilly and Co's pre-market trading rose more than 2%, beating Novo-Nordisk in the first comparative trial.

Breakings ·  Dec 4 19:49

Eli Lilly and Co's pre-market trading rose sharply in the short term, now up more than 2%; Novo-Nordisk is currently down 0.62%. On the news side, according to Bloomberg, Eli Lilly's weight loss drug Zepbound beat Novo-Nordisk's Wegovy in the first comparative trial.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment